bluebird bio

bluebird bio, Inc. (Nasdaq: BLUE) today announced that its investigational LentiGlobin™ gene therapy for the treatment of adolescent and adult patients with transfusion-dependent β-thalassemia (TDT) and a non-β0/β0 genotype, was granted an accelerated assessment by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), for its upcoming marketing authorization application (MAA).

bluebird bio, Inc. announced the pricing of an underwritten public offering of 3,384,616 shares of its common stock at a public offering price of $162.50 per share

bluebird bio, Inc. announced that it has commenced an underwritten public offering of $400 million of its common stock.

Precision BioSciences CSO Derek Jantz will present and join a panel discussion during the DIA (Drug Information Association) 2018 conference.

First Group C patient generating a normal total hemoglobin of 14.2 g/dL with over 60% anti-sickling HbAT87Q at 6 months

bluebird bio, Inc. announced that new data from the completed Phase 1/2 Northstar study will be presented in an oral session at the 23rd Annual Congress of the European Hematology Association.

bluebird bio, Inc. announced that members of the management team will present at the following upcoming investor conferences in June:

Cerebral adrenoleukodystrophy is a rare, serious and life-threatening hereditary neurological disorder.

bluebird bio, Inc. reported financial results and business highlights for the first quarter ended March 31, 2018.

bluebird bio, Inc. announced interim data published in the New England Journal of Medicine (NEJM) from two separate two-year clinical studies investigating the potential for LentiGlobin™ gene therapy to eliminate or reduce chronic blood transfusions in patients with transfusion-dependent β-thalassemia (TDT).